Champions Oncology(US:CSBR)2026-03-12 20:56Revenue Performance - Oncology revenue for the three months ended January 31, 2026, was $16.6 million, a decrease of 2.8% from $17.0 million in the same period in 2025 [101]. - For the nine months ended January 31, 2026, oncology revenue totaled $45.6 million, an increase of 2.2% from $44.6 million in the same period in 2025 [101]. - Revenue from TOS data licenses was $0 for the three months ended January 31, 2026, compared to $4.5 million for the same period in 2025 [105]. Cost and Expense Analysis - Cost of oncology revenue increased by $2.2 million or 33.5% to $8.8 million for the three months ended January 31, 2026, compared to $6.6 million in the prior year [107]. - Research and development expenses for the three months ended January 31, 2026, were $2.3 million, an increase of 32.1% from $1.7 million in the same period in 2025 [108]. - Total costs and operating expenses for the three months ended January 31, 2026, were $16.8 million, an increase of 34.3% from $12.5 million in the prior year [100]. - Sales and marketing expenses increased to $2.7 million for the three months ended January 31, 2026, up 47.6% from $1.8 million in the same period in 2025 [111]. - General and administrative expenses rose to $3.0 million for the three months ended January 31, 2026, an increase of 24.1% from $2.4 million in the same period in 2025 [112]. - The increase in sales and marketing expenses was primarily driven by higher compensation expenses related to the expansion of the Company's commercial organization [111]. - General and administrative expenses were primarily attributed to higher compensation expenses associated with executive leadership changes and increased IT infrastructure costs [112]. Financial Position - The company had a net loss of $508,000 for the nine months ended January 31, 2026, compared to a net income of $6.5 million for the same period in 2025 [99]. - As of January 31, 2026, the company had cash of $7.1 million and an accumulated deficit of approximately $80.4 million [99]. - Net cash used in operating activities was $2.5 million for the nine months ended January 31, 2026, compared to net cash provided of $518,000 in the same period in 2025 [113]. - Net cash used in investing activities was approximately $302,000 for the nine months ended January 31, 2026, compared to $136,000 in the same period in 2025 [114]. - Net cash provided by financing activities was $118,000 for the nine months ended January 31, 2026, down from $202,000 in the same period in 2025 [115]. - The Company has no off-balance sheet debt or similar obligations [118]. Strategic Outlook - The company expects that transitioning radiolabeling work into its laboratories will lead to a more favorable cost structure in the coming quarters [107]. - The company is evaluating strategic options to create additional value from its drug discovery business, which may include potential spin-out transactions or capital raises [98]. Accounting and Reporting - There have been no changes to critical accounting policies during the nine months ended January 31, 2026 [117]. - The Company is classified as a smaller reporting company and is not required to provide additional market risk disclosures [119].